ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,469.30
0.39%
US Tech 100
19,174.00
1.14%
다우존스 지수
39,112.16
-0.76%
Bitcoin
61,624.36
-0.30%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. POINT Biopharma Global Inc (PNT)

  7. POINT Biopharma Global Inc (PNT) 뉴스

PNT

POINT Biopharma Global (PNT)

POINT Biopharma Global Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:PNT
일자시간출처헤드라인심볼기업
2024/01/0821:00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PNTPOINT Biopharma Global Inc
2024/01/0314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PNTPOINT Biopharma Global Inc
2024/01/0314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2807:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2723:44Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2723:43Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2723:42Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2723:41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2723:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2722:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/2722:31PR Newswire (US)Lilly Completes Acquisition of POINT BiopharmaNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/1822:14Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
2023/12/1821:30GlobeNewswire Inc.Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate CancerNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/1820:45PR Newswire (US)Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023NASDAQ:PNTPOINT Biopharma Global Inc
2023/12/0520:25IH Market NewsMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and MoreNASDAQ:PNTPOINT Biopharma Global Inc
2023/12/0421:22Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
2023/12/0420:45PR Newswire (US)Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023NASDAQ:PNTPOINT Biopharma Global Inc
2023/11/1721:05Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
2023/11/1720:45PR Newswire (US)Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023NASDAQ:PNTPOINT Biopharma Global Inc
2023/11/1521:00Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
2023/11/1506:33PR Newswire (US)Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT BiopharmaNASDAQ:PNTPOINT Biopharma Global Inc
2023/11/1321:30GlobeNewswire Inc.POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:PNTPOINT Biopharma Global Inc
2023/11/1321:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PNTPOINT Biopharma Global Inc
 검색 관련기사 보기:NASDAQ:PNT

최근 히스토리

NYSE
MRK
Merck
PM
XAUUSD
Gold vs US Dollar
NYSE
AXP
American Express
NASDAQ
NVDA
NVIDIA
NYSE
XOM
Exxon Mobil
AMEX
XLE
Energy Select Sector SPDR
AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
NYSE
MCD
McDonalds
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
DIS
Walt Disney
CCOM
US30
US 30
COIN
BTCUSD
Bitcoin
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USI
USTECH100
US Tech 100
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유